Market research
01P.F Medpace Holdings, Inc
F EUR Healthcare
Latest close
As of 27 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 17B
- P/E ratio
- 38.34
- Analyst target
- 170.5
- Dividend yield
- Not available
- Beta
- 1.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 17B
- P/E ratio
- 38.34
- Analyst target
- 170.5
- Dividend yield
- Not available
- Beta
- 1.18
About
About Medpace Holdings, Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Research context
Medpace Holdings, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 01P.F discussion.
5 years, 6 months ago
Medpace Holdings, Inc is currently in a long term uptrend where the price is trading 21.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Medpace Holdings, Inc's total revenue rose by 13.0% to $260M since the same quarter in the previous year.
Its net income has increased by 70.6% to $51M since the same quarter in the previous year.
Finally, its free cash flow grew by 90.9% to $98M since the same quarter in the previous year.
Based on the above factors, Medpace Holdings, Inc gets an overall score of 5/5.